(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 September 2025 (25.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/198687 A1

(51) International Patent Classification:
A61K 31/138 (2006.01) *A61K 31/5377* (2006.01)
A61K 31/167 (2006.01) *A61K 45/06* (2006.01)
A61K 31/4245 (2006.01) *A61P 9/00* (2006.01)

(21) International Application Number:
PCT/US2024/061908

(22) International Filing Date:
26 December 2024 (26.12.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/567,935	20 March 2024 (20.03.2024)	US
63/568,801	22 March 2024 (22.03.2024)	US
63/572,074	29 March 2024 (29.03.2024)	US
63/636,352	19 April 2024 (19.04.2024)	US
63/650,810	22 May 2024 (22.05.2024)	US
63/656,504	05 June 2024 (05.06.2024)	US
63/665,947	28 June 2024 (28.06.2024)	US
63/672,627	17 July 2024 (17.07.2024)	US
63/681,620	09 August 2024 (09.08.2024)	US
63/690,691	04 September 2024 (04.09.2024)	US
63/697,315	20 September 2024 (20.09.2024)	US

(71) Applicant: **CYTOKINETICS, INCORPORATED** [US/US]; 350 Oyster Point Blvd., South San Francisco, California 94080 (US).

(72) Inventors: **MALIK, Fady**; c/o Cytokinetics, Incorporated, 350 Oyster Point Blvd., South San Francisco, California 94080 (US). **KUPFER, Stuart**; c/o Cytokinetics, Incorporated, 350 Oyster Point Blvd., South San Francisco, California 94080 (US). **HEITNER, Stephen B.**; c/o Cytokinetics, Incorporated, 350 Oyster Point Blvd., South San Francisco, California 94080 (US). **JACOBY, Daniel Louis**; c/o Cytokinetics, Incorporated, 350 Oyster Point Blvd., South San Francisco, California 94080 (US). **MENG, Lixin**; c/o Cytokinetics, Incorporated, 350 Oyster Point Blvd., South San Francisco, California 94080 (US).

(74) Agent: **ELLINGER, Martin** et al.; Morrison & Foerster LLP, 12531 High Bluff Drive, Suite 100, San Diego, California 92130-2040 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

(54) Title: METHODS FOR TREATING HEART DISEASES



FIG. 3A

(57) Abstract: Provided herein are methods of treating patients by administering aficamten, or a pharmaceutically acceptable salt thereof, including in combination with beta blockers. The treatment methods include improving heart rate reserve, peak metabolic equivalents (METs), exercise duration, peak oxygen uptake (pVCE) as well as other parameters related to exercise capacity.

[Continued on next page]

WO 2025/198687 A1

CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*